



Réhabilitation précoce en réanimation : comment limiter les altérations fonctionnelles et le Handicap post-Réanimation

JM Constantin, M.D. Ph.D.

Pôle de Médecine PériOpératoire

Réanimations et USC

CHU Clermont-Ferrand, France

Liens d'intérêt

LFB
MSD
BAXTER
DRAGER
MAQUET
FRESENIUS-KABI
HOSPAL
GE
ASTELLAS
ABBOTT
VIASYS
ALERE
EDWARDS
PFIZER
PHILIPS
HAMILTON
MASSIMO
BBRAUN
BiRD-Corporation
ASTUTE Medical

Ministère de la santé
PHRC
ANR-DGOS



UdA

EA 72-81

R2D2






**Réhabilitation précoce en réanimation :
comment limiter les altérations fonctionnelles et
le Handicap post-Réanimation**


Réanimation



Admission en réa des baby boomers







Réanimation

+ de patients

+ suppléances d'organe

+ agés

+ comorbidités

+ cancer

Réanimation


+ de patients

+ suppléances d'organe

+ agés

+ comorbidités

+ cancer




- Sarcopénie
- Anorexie
- cachexie
- Dénutrition
- ...

**Réhabilitation précoce en réanimation :
comment limiter les altérations fonctionnelles et
le Handicap post-Réanimation**

le Handicap









Right Lung



Left Lung



% patients



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

FEBRUARY 20, 2003


VOL. 348 NO. 8

One-Year Outcomes in Survivors of the Acute Respiratory Distress Syndrome

Margaret S. Herridge, M.D., M.P.H., Angela M. Cheung, M.D., Ph.D., Catherine M. Tansey, M.Sc.,
Andrea Matte-Martyn, B.Sc., Natalia Diaz-Granados, B.Sc., Fatma Al-Saidi, M.D., Andrew B. Cooper, M.D.,
Cameron B. Guest, M.D., C. David Mazer, M.D., Sangeeta Mehta, M.D., Thomas E. Stewart, M.D., Aiala Barr, Ph.D.,
Deborah Cook, M.D., and Arthur S. Slutsky, M.D., for the Canadian Critical Care Trials Group

One-Year Outcomes in Survivors of the Acute Respiratory Distress Syndrome

Margaret S. Herridge, M.D., M.P.H., Angela M. Cheung, M.D., Ph.D., Catherine M. Tansey, M.Sc.,
 Andrea Matte-Martyn, B.Sc., Natalia Diaz-Granados, B.Sc., Fatma Al-Saidi, M.D., Andrew B. Cooper, M.D.,
 Cameron B. Guest, M.D., C. David Mazer, M.D., Sangeeta Mehta, M.D., Thomas E. Stewart, M.D., Aiala Barr, Ph.D.,
 Deborah Cook, M.D., and Arthur S. Slutsky, M.D., for the Canadian Critical Care Trials Group



Variable	3 Mo (N=71)*	6 Mo (N=77)†	12 Mo (N=80)‡
	<i>median (interquartile range)</i>		
Forced vital capacity (% of predicted)	72 (57–86)	80 (68–94)	85 (71–98)
Forced expiratory volume in one second (% of predicted)	75 (58–92)	85 (69–98)	86 (74–100)
Total lung capacity (% of predicted)§	92 (77–97)	92 (83–101)	95 (81–103)
Residual volume (% of predicted)§	107 (87–121)	97 (82–117)	105 (90–116)
Carbon monoxide diffusion capacity (% of predicted)§¶	63 (54–77)	70 (58–82)	72 (61–86)

Etudes Anciennes

Vt > 10-12 ml/kg

Pas de contrôle de la Pplat

Pneumothorax

ViLi

**Réhabilitation précoce en réanimation :
comment limiter les altérations fonctionnelles et
le Handicap post-Réanimation**

altérations fonctionnelles

The **NEW ENGLAND**
JOURNAL *of* **MEDICINE**

ESTABLISHED IN 1812

APRIL 7, 2011


VOL. 364 NO. 14

**Functional Disability 5 Years after Acute Respiratory
Distress Syndrome**

Margaret S. Herridge, M.D., M.P.H., Catherine M. Tansey, M.Sc., Andrea Matté, B.Sc., George Tomlinson, Ph.D.,
Natalia Diaz-Granados, M.Sc., Andrew Cooper, M.D., Cameron B. Guest, M.D., C. David Mazer, M.D.,
Sangeeta Mehta, M.D., Thomas E. Stewart, M.D., Paul Kudlow, B.Sc., Deborah Cook, M.D.,
Arthur S. Slutsky, M.D., and Angela M. Cheung, M.D., Ph.D.,
for the Canadian Critical Care Trials Group



Functional Disability 5 Years after Acute Respiratory Distress Syndrome

Margaret S. Herridge, M.D., M.P.H., Catherine M. Tansey, M.Sc., Andrea Matté, B.Sc., George Tomlinson, Ph.D.,
Natalia Diaz-Granados, M.Sc., Andrew Cooper, M.D., Cameron B. Guest, M.D., C. David Mazer, M.D.,
Sangeeta Mehta, M.D., Thomas E. Stewart, M.D., Paul Kudlow, B.Sc., Deborah Cook, M.D.,
Arthur S. Slutsky, M.D., and Angela M. Cheung, M.D., Ph.D.,
for the Canadian Critical Care Trials Group




Functional Disability 5 Years after Acute Respiratory Distress Syndrome

Margaret S. Herridge, M.D., M.P.H., Catherine M. Tansey, M.Sc., Andrea Matté, B.Sc., George Tomlinson, Ph.D.,
Natalia Diaz-Granados, M.Sc., Andrew Cooper, M.D., Cameron B. Guest, M.D., C. David Mazer, M.D.,
Sangeeta Mehta, M.D., Thomas E. Stewart, M.D., Paul Kudlow, B.Sc., Deborah Cook, M.D.,
Arthur S. Slutsky, M.D., and Angela M. Cheung, M.D., Ph.D.,
for the Canadian Critical Care Trials Group



Functional Disability 5 Years after Acute Respiratory Distress Syndrome


Margaret S. Herridge, M.D., M.P.H., Catherine M. Tansey, M.Sc., Andrea Matté, B.Sc., George Tomlinson, Ph.D., Natalia Diaz-Granados, M.Sc., Andrew Cooper, M.D., Cameron B. Guest, M.D., C. David Mazer, M.D., Sangeeta Mehta, M.D., Thomas E. Stewart, M.D., Paul Kudlow, B.Sc., Deborah Cook, M.D., Arthur S. Slutsky, M.D., and Angela M. Cheung, M.D., Ph.D.,
 for the Canadian Critical Care Trials Group



No. at Risk	109	92	86	79	77	74	69	64
No. for 6-Min Walk	80	78	81	60	64	64	57	54
No. for SF-36	67	74	74	56	57	57	49	50



Radiologic Outcomes at 5 Years After Severe ARDS




Functional Disability 5 Years after Acute Respiratory
Distress Syndrome


Margaret S. Herridge, M.D., M.P.H., Catherine M. Tansey, M.Sc., Andrea Matté, B.Sc., George Tomlinson, Ph.D.,
Natalia Diaz-Granados, M.Sc., Andrew Cooper, M.D., Cameron B. Guest, M.D., C. David Mazer, M.D.,
Sangeeta Mehta, M.D., Thomas E. Stewart, M.D., Paul Kudlow, B.Sc., Deborah Cook, M.D.,
Arthur S. Slutsky, M.D., and Angela M. Cheung, M.D., Ph.D.,
for the Canadian Critical Care Trials Group

In summary, young, previously working patients with ARDS who have few coexisting illnesses may not recover completely and may have ongoing functional limitations after an episode of critical illness. This may be attributed to persistent ICU-acquired weakness, in addition to a variety of other physical and mental health impairments. Family members may also have psychological dysfunction, which may further compromise outcomes. The health burden of critical illness may be likened to that of chronic disease with similar health care utilization. Research priorities include a better understanding of the pathophysiology of ICU-acquired weakness and an evaluation of the effects of a customized, family-centered, rehabilitation program on long-term outcomes after a critical illness.

"ICU acquired weakness"





- ❑ **Myopathie**
Atrophie fibres type II
- ❑ **Neuropathie**
Dégénération axonale
- ❑ **Neuromyopathies**
- ❑ **Atrophie diffuse**





Case

Control

Fiber Size



Slow Myosin Heavy Chain



Fast Myosin Heavy Chain







Table 3. Clinical Risk Factors and Pathophysiological Features of Critical Illness Polyneuropathy and Critical Illness Myopathy.

Variable	Reference	Pathophysiological processes
Clinical risk factors of both critical illness polyneuropathy and critical illness myopathy		Critical illness polyneuropathy
Female sex	De Jonghe et al. ¹¹	Motor nerves affected more than sensory nerves
Sepsis	Garnacho-Montero et al. ²⁸	Secondary denervation muscle injury (myopathy)
Catabolic state	Trojaborg et al., ¹⁵ Garnacho-Montero et al. ²⁸	Proposed mechanisms
Multiorgan system failure	De Jonghe et al. ¹¹	Nerve ischemia
Systemic inflammatory response syndrome	Jaber et al., ³³ Levine et al. ³⁴	Nerve microvascular injury
Long duration of mechanical ventilation	De Jonghe et al. ¹¹	Nerve mitochondrial injury
Immobility	Levine et al., ³² Papazian et al., ³⁹ Iwashyna et al. ⁴¹	Sodium channelopathy
Hyperglycemia	Van den Berghe et al. ¹³	Critical illness myopathy
Glucocorticoids	De Jonghe et al. ¹¹	Primary myopathy — selective myosin loss, muscle necrosis (e.g., ubiquitin–proteasome proteolysis)
Neuromuscular blocking agents	MacFarlane and Rosenthal, ³ Leatherman et al. ¹²	Mitochondrial dysfunction
		Oxidative stress
		Sodium channelopathy


Skeletal morbidity among survivors of critical illness*

Neil R. Orford, MBBS, FCICM; Kym Saunders, MBBS, FCICM; Elizabeth Merriman, BSc(Hons); Margaret Henry, BSc(Hons); Julie Pasco, BSc(Hons); Peter Stow, MBBS, FCICM; Mark Kotowicz, MBBS, FRACP




Ossifications hétérotopiques

- Comas
- Lésions de la moelle épinière
- Pancréatites aiguës
- **Immobilisation prolongée en réanimation**



Jacobs et al, Rheumatology 99



Sebastiani et al, Clin Rheumatol 02

The **NEW ENGLAND**
JOURNAL *of* **MEDICINE**

ESTABLISHED IN 1812

APRIL 7, 2011


VOL. 364 NO. 14

**Functional Disability 5 Years after Acute Respiratory
Distress Syndrome**

Margaret S. Herridge, M.D., M.P.H., Catherine M. Tansey, M.Sc., Andrea Matté, B.Sc., George Tomlinson, Ph.D.,
Natalia Diaz-Granados, M.Sc., Andrew Cooper, M.D., Cameron B. Guest, M.D., C. David Mazer, M.D.,
Sangeeta Mehta, M.D., Thomas E. Stewart, M.D., Paul Kudlow, B.Sc., Deborah Cook, M.D.,
Arthur S. Slutsky, M.D., and Angela M. Cheung, M.D., Ph.D.,
for the Canadian Critical Care Trials Group

**Score
Global
de santé
Mental**


**Score
Global
de santé
Physique**



**2½
ans**

Theodore J. Iwashyna, MD, PhD
 E. Wesley Ely, MD, MPH
 Dylan M. Smith, PhD
 Kenneth M. Langa, MD, PhD

Long-term Cognitive Impairment and Functional Disability Among Survivors of Severe Sepsis



Temps (années) →


LEUCO-ENCEPHALOPATHIE SEPTIQUE

Sharshar et al, Intensive Care Med 2007


Grade I



Grade II



Grade III



le Handicap



Syndrome de stress post traumatique (PTSD)




SSPT : trouble anxieux sévère qui se manifeste à la suite d'une expérience vécue comme traumatisante (attentats, viol, guerre...).

Syndrome de stress post traumatique (PTSD)



Social support during intensive care unit stay might improve mental impairment and consequently health-related quality of life in survivors of severe acute respiratory distress syndrome

Maria Deja*, Claudia Denke*, Steffen Weber-Carstens, Jürgen Schröder, Christian E Pille, Frank Hokema, Konrad J Falke and Udo Kaisers




57±32 mois
PTSS-10
SF-36

Social support during intensive care unit stay might improve mental impairment and consequently health-related quality of life in survivors of severe acute respiratory distress syndrome


Maria Deja*, Claudia Denke*, Steffen Weber-Carstens, Jürgen Schröder, Christian E Pille, Frank Hokema, Konrad J Falke and Udo Kaisers

PTSD : 30% des patients



One-Year Outcomes in Survivors of the Acute Respiratory Distress Syndrome

Wagner E, Browder M, Griffin M, et al. *N Engl J Med*. 2008;359:2638-47.



Variable	3 Mo (N=71)*	6 Mo (N=77)†	12 Mo (N=80)‡
median (interquartile range)			
Forced vital capacity (% of predicted)	72 (57-84)	80 (68-94)	85 (71-98)
Forced expiratory volume in one second (% of predicted)	75 (58-92)	85 (69-98)	86 (74-100)
Total lung capacity (% of predicted)§	92 (77-97)	92 (83-101)	95 (81-103)
Residual volume (% of predicted)§	107 (87-123)	97 (82-117)	105 (90-116)
Carbon monoxide diffusion capacity (% of predicted)¶	63 (54-77)	70 (58-82)	72 (61-86)

RECOMMANDATIONS FORMALISÉES D'EXPERTS

Nutrition artificielle en réanimation
Guidelines for nutrition support in critically ill patient

J.-Y. Lefrant ^{a,*}, D. Hurel ^b, N.J. Cano ^{c,d,e}, C. Ichai ^f, J.-C. Preiser ^g, F. Tamion ^h

^a Services des réanimations, division anesthésie réanimation douleur urgence, CHU de Nîmes, place du Pr-Robert-Debré, 30029 Nîmes cedex 9, France

^b Service de réanimation médico-chirurgicale, centre hospitalier François-Quesnay, 2, boulevard Sully, 78201 Mantes-la-Jolie cedex, France

^c Service de nutrition, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand cedex, France

^d Unité de nutrition humaine, Clermont université, université d'Auvergne, BP 10448, 63000 Clermont-Ferrand, France

^e Inra, UMR 1019, UNH, CRNH Auvergne, 63000 Clermont-Ferrand, France

^f Service de réanimation médico-chirurgicale, hôpital Saint-Roch, CHU de Nice, 5, rue Pierre-Dévoluy, 06006 Nice cedex 1, France

^g Service des soins intensifs, hôpital universitaire Erasme, 808, route de Lennik, 1070 Bruxelles, Belgique

^h Service de réanimation médicale, hôpital Charles-Nicolle, CHU de Rouen, 1, rue de Germont, 76081 Rouen cedex, France



Réanimation

+ de patients

+ suppléances d'organe


+ agés

+ comorbidités

+ cancer

- Sarcopénie
- Anorexie
- cachexie
- Dénutrition
- ...

"ICU acquired weakness"



- ❑ Myopathie
Atrophie fibres type II
- ❑ Neuropathie
Dégénération axonale
- ❑ Neuromyopathies
- ❑ Atrophie diffuse

Initial Trophic vs Full Enteral Feeding in Patients With Acute Lung Injury The EDEN Randomized Trial

The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Study Group

BACKGROUND: Most patients cannot eat, but long periods of tube feeding may be necessary. We compared early trophic feeding with full enteral feeding in patients with acute lung injury. **DESIGN, SETTING, AND PARTICIPANTS:** The EDEN study, a randomized open-label, multicenter trial, involved 1000 patients with acute lung injury requiring mechanical ventilation for at least 48 hours. **MEASUREMENTS AND MAIN RESULTS:** Patients were randomized to receive either trophic or full enteral feeding for the first 7 days. **CONCLUSIONS:** Patients who received trophic feeding had lower mortality and shorter mechanical ventilation times compared with those who received full enteral feeding.

ORIGINAL ARTICLE

Permissive Underfeeding or Standard Enteral Feeding in Critically Ill Adults

Yassem M. Arabi, M.D., Abdulaziz S. Aldawood, M.D., Samir H. Haddad, M.D., Hassan M. Al-Dorzi, M.D., Hani M. Tamim, M.P.H., Ph.D., Guyane Jones, M.D., Sangenta Mehta, M.D., Lavinia McIntyre, M.D., Othman Sulaiman, M.D., Maram H. Sakkijha, R.D., Mubashar Sadiq, M.B., B.S., and Lara Alfehri, M.S.N., for the Permit Trial Group*

ABSTRACT

BACKGROUND: The appropriate caloric goal for critically ill adults is unclear. We evaluated the effect of restriction of nonprotein calories (permissive underfeeding), as compared with standard enteral feeding, on 90-day mortality among critically ill adults, with maintenance of the full recommended amount of protein in both groups.

METHODS: At seven centers, we randomly assigned 194 critically ill adults with a medical, surgical, or trauma admission category to permissive underfeeding (40 to 60% of calculated caloric requirements) or standard enteral feeding (70 to 100%) for up to 34 days while maintaining a similar protein intake in the two groups. The primary outcome was 90-day mortality.

RESULTS: Baseline characteristics were similar in the two groups; 96.3% of the patients were receiving mechanical ventilation. During the intervention period, the permissive underfeeding group received lower mean (SD) calories than did the standard-feeding group (832±297 kcal per day vs. 1299±467 kcal per day, P<0.001, 46±14% vs. 71±22% of caloric requirements, P<0.001). Protein intake was similar in the two groups (57±24 g per day and 59±25 g per day, respectively, P=0.26). The 90-day mortality was similar (121 of 445 patients [27.2%] in the permissive-underfeeding group and 127 of 440 patients [28.9%] in the standard-feeding group) (relative risk with permissive underfeeding, 0.94; 95% confidence interval [CI], 0.76 to 1.16; P=0.58). No serious adverse events were reported; there were no significant between-group differences with respect to feeding intolerance, diarrhea, infections acquired in the intensive care unit (ICU), or ICU or hospital length of stay.

CONCLUSIONS: Enteral feeding to deliver a moderate amount of nonprotein calories to critically ill adults was not associated with lower mortality than that associated with planned delivery of a full amount of nonprotein calories. (Registered by the ClinicalTrials.gov Identifier: NCT01149981.)

ORIGINAL ARTICLE

Permissive Underfeeding or Standard Enteral Feeding in Critically Ill Adults

Yassem M. Arabi, M.D., Abdulaziz S. Aldawood, M.D., Samir H. Haddad, M.D., Hassan M. Al-Dorzi, M.D., Hani M. Tamim, M.P.H., Ph.D., Guyane Jones, M.D., Sangenta Mehta, M.D., Lavinia McIntyre, M.D., Othman Sulaiman, M.D., Maram H. Sakkijha, R.D., Mubashar Sadiq, M.B., B.S., and Lara Alfehri, M.S.N., for the Permit Trial Group*

ABSTRACT

BACKGROUND: The appropriate caloric goal for critically ill adults is unclear. We evaluated the effect of restriction of nonprotein calories (permissive underfeeding), as compared with standard enteral feeding, on 90-day mortality among critically ill adults, with maintenance of the full recommended amount of protein in both groups.

METHODS: At seven centers, we randomly assigned 194 critically ill adults with a medical, surgical, or trauma admission category to permissive underfeeding (40 to 60% of calculated caloric requirements) or standard enteral feeding (70 to 100%) for up to 34 days while maintaining a similar protein intake in the two groups. The primary outcome was 90-day mortality.

RESULTS: Baseline characteristics were similar in the two groups; 96.3% of the patients were receiving mechanical ventilation. During the intervention period, the permissive underfeeding group received lower mean (SD) calories than did the standard-feeding group (832±297 kcal per day vs. 1299±467 kcal per day, P<0.001, 46±14% vs. 71±22% of caloric requirements, P<0.001). Protein intake was similar in the two groups (57±24 g per day and 59±25 g per day, respectively, P=0.26). The 90-day mortality was similar (121 of 445 patients [27.2%] in the permissive-underfeeding group and 127 of 440 patients [28.9%] in the standard-feeding group) (relative risk with permissive underfeeding, 0.94; 95% confidence interval [CI], 0.76 to 1.16; P=0.58). No serious adverse events were reported; there were no significant between-group differences with respect to feeding intolerance, diarrhea, infections acquired in the intensive care unit (ICU), or ICU or hospital length of stay.

CONCLUSIONS: Enteral feeding to deliver a moderate amount of nonprotein calories to critically ill adults was not associated with lower mortality than that associated with planned delivery of a full amount of nonprotein calories. (Registered by the ClinicalTrials.gov Identifier: NCT01149981.)

ORIGINAL ARTICLE

Trial of the Route of Early Nutritional Support in Critically Ill Adults

Sheila E. Harvey, Ph.D., Francesca Perrott, M.Sc., David A. Harrison, Ph.D., Danielle E. Bear, M.B., Ella Sagarin, M.Sc., Richard Beale, M.B., B.S., Geoff Bellinger, M.D., Richard Leonard, M.B., B.Chir., Michael G. Mythen, M.D., and Kathryn M. Rowan, Ph.D., for the CALORIES Trial Investigators*

ABSTRACT

BACKGROUND: Uncertainty exists about the most effective route for delivery of early nutritional support in critically ill adults. We hypothesized that delivery through the parenteral route is superior to that through the enteral route.

METHODS: We conducted a pragmatic, randomized trial involving adults with an unplanned admission to one of 50 English intensive care units. We randomly assigned patients who could be fed through either the parenteral or the enteral route to a delivery route, with nutritional support initiated within 36 hours after admission and continued for up to 5 days. The primary outcome was all-cause mortality at 30 days.

RESULTS: We enrolled 2400 patients; 2388 (99.5%) were included in the analysis (1191 in the parenteral group and 1197 in the enteral group). By 30 days, 39% of 1188 patients (33.7%) in the parenteral group and 40% of 1195 patients (34.2%) in the enteral group had died (relative risk in parenteral group, 0.87; 95% confidence interval, 0.66 to 1.16; P=0.37). There were significant reductions in the parenteral group, as compared with the enteral group, in rates of hypoglycemia (44 patients [3.7%] vs. 74 patients [6.2%]; P=0.006) and vomiting (300 patients [25.4%] vs. 194 patients [16.2%]; P<0.001). There were no significant differences between the parenteral group and the enteral group in the mean number of treated infectious complications (6.22 vs. 6.21; P=0.72), 90-day mortality (442 of 1184 patients [37.3%] vs. 464 of 1188 patients [39.1%]; P=0.40), in rates of 34 other secondary outcomes, or in rates of adverse events. Caloric intake was similar in the two groups, with the target intake not achieved in most patients.

CONCLUSIONS: We found no significant difference in 30-day mortality associated with the route of delivery of early nutritional support in critically ill adults. (Registered by the ClinicalTrials.gov Identifier: NCT01171861.)

ORIGINAL ARTICLE

Early versus On-Demand Nasoenteric Tube Feeding in Acute Pancreatitis

O.J. Bakker, S. van Brunschot, H.C. van Santvoort, M.C. Bruijckmans, T.J. Bollen, M.A. Bommelaere, C.H. Dejong, H. van Gool, K. Bannink, U. Alward, M.L. Buisson, W.M. van Grvenstein, J. Heerink, A.P. Houdijk, J.M. Jansen, T.M. Karim, E.R. Manasseh, V.B. Nannanburana, A.P. Schaapherder, G.P. van der Schelling, M.P. Schreurs, B.W.M. Spanier, A. Ten, J. Vreth, B.S. Wittevoort, R.J. Witterman, I.M. Albertsson, M.J. Breen, M.C. Dijkgraaf, B. van Erven, and H.G. Gooszen, for the Dutch Pancreatitis Study Group

ABSTRACT

BACKGROUND: Early enteral feeding through a nasoenteric feeding tube is often used in patients with acute pancreatitis to prevent further infections, but evidence to support this strategy is limited. We conducted a multicenter, randomized trial comparing early nasoenteric tube feeding with an oral diet at 72 hours after presentation to the emergency department in patients with acute pancreatitis.

METHODS: We studied patients with acute pancreatitis who were at high risk for complications on the basis of an Acute Physiology and Chronic Health Evaluation II score of 8 or higher on a scale of 0 to 71, with higher scores indicating more severe disease, as well as modified Glasgow scores of 3 or higher on a scale of 0 to 8, with higher scores indicating more severe disease, or a serum C-reactive protein level of more than 150 mg per liter. Patients were randomly assigned to nasoenteric tube feeding after presentation (on-demand group) or to an oral diet initiated 72 hours after presentation (early group). The primary end point was a composite of major infectious pancreatic necrosis, bacteremia, or pneumonia or death during 6 months of follow-up.

RESULTS: A total of 208 patients were enrolled at 19 Dutch hospitals. The primary end point occurred in 30 of 101 patients (30%) in the early group and in 28 of 107 (26%) in the on-demand group (risk ratio, 1.25; 95% confidence interval, 0.79 to 1.96; P=0.30). There were no significant differences between the early group and the on-demand group in the rate of major infection (25% and 26%, respectively; P=0.87) or death (11% and 7%, respectively; P=0.37). In the on-demand group, 77 patients (70%) achieved an oral diet and did not require tube feeding.

CONCLUSIONS: This trial did not show the superiority of early nasoenteric tube feeding, as compared with an oral diet after 72 hours, in reducing the rate of infection or death in patients with acute pancreatitis at high risk for complications. (Registered by the Netherlands Organization for Health Research and Development and others; Pancreatic Current Controlled Trials number, NCT01182095.)

ORIGINAL ARTICLE

Early Parenteral Nutrition in Critically Ill Patients with Short-term Relative Contraindications to Early Enteral Nutrition: A Randomized Controlled Trial

David A. Harrison, Ph.D., Francesca Perrott, M.Sc., David A. Harrison, Ph.D., Danielle E. Bear, M.B., Ella Sagarin, M.Sc., Richard Beale, M.B., B.S., Geoff Bellinger, M.D., Richard Leonard, M.B., B.Chir., Michael G. Mythen, M.D., and Kathryn M. Rowan, Ph.D., for the CALORIES Trial Investigators*

ABSTRACT

BACKGROUND: Uncertainty exists about the most effective route for delivery of early nutritional support in critically ill adults. We hypothesized that delivery through the parenteral route is superior to that through the enteral route.

METHODS: We conducted a pragmatic, randomized trial involving adults with an unplanned admission to one of 50 English intensive care units. We randomly assigned patients who could be fed through either the parenteral or the enteral route to a delivery route, with nutritional support initiated within 36 hours after admission and continued for up to 5 days. The primary outcome was all-cause mortality at 30 days.


RESULTS: We enrolled 2400 patients; 2388 (99.5%) were included in the analysis (1191 in the parenteral group and 1197 in the enteral group). By 30 days, 39% of 1188 patients (33.7%) in the parenteral group and 40% of 1195 patients (34.2%) in the enteral group had died (relative risk in parenteral group, 0.87; 95% confidence interval, 0.66 to 1.16; P=0.37). There were significant reductions in the parenteral group, as compared with the enteral group, in rates of hypoglycemia (44 patients [3.7%] vs. 74 patients [6.2%]; P=0.006) and vomiting (300 patients [25.4%] vs. 194 patients [16.2%]; P<0.001). There were no significant differences between the parenteral group and the enteral group in the mean number of treated infectious complications (6.22 vs. 6.21; P=0.72), 90-day mortality (442 of 1184 patients [37.3%] vs. 464 of 1188 patients [39.1%]; P=0.40), in rates of 34 other secondary outcomes, or in rates of adverse events. Caloric intake was similar in the two groups, with the target intake not achieved in most patients.

ONLINE FIRST

Initial Trophic vs Full Enteral Feeding in Patients With Acute Lung Injury

The EDEN Randomized Trial




JAMA, February 22/29



Early Parenteral Nutrition in Critically Ill Patients With Short-term Relative Contraindications to Early Enteral Nutrition

A Randomized Controlled Trial

May 20, 2013



Early Parenteral Nutrition in Critically Ill Patients With Short-term Relative Contraindications to Early Enteral Nutrition

May 20, 2013

A Randomized Controlled Trial

Table 2. Mortality, Quality of Life, and Length of Stay

	Standard Care (n = 680) ^a	Early PN (n = 678) ^a	Risk Difference, % (95% CI)	Odds Ratio (95% CI)	P Value
Deaths before study day 60, No. (%)	155 (22.8)	146 (21.5)	-1.26 (-6.6 to 4.1)	0.93 (0.71 to 1.21)	.60
Covariate-adjusted deaths before study day 60 ^b			0.04 (-4.2 to 4.3)	1.00 (0.76 to 1.31)	>.99
Quality of life and physical function, mean (SD) ^c	(n = 525)	(n = 532)	Difference (95% CI)		
RAND-36 general health status ^d	45.5 (26.8) (n = 516)	49.8 (27.6) (n = 525)	4.3 (0.95 to 7.58)		.01
ECOG performance status ^e	1.53 (1.1) (n = 516)	1.51 (1.1) (n = 525)	-0.02 (-0.15 to 0.11)		.70
RAND-36 physical function ^f	40.7 (29.6) (n = 513)	42.5 (30.8) (n = 524)	1.8 (-1.85 to 5.52)		.33
Discharge status and length of stay	(n = 682)	(n = 681)	Difference (95% CI)		
ICU stay, mean (95% CI), d	9.3 (8.9 to 9.7)	8.6 (8.2 to 9.0)	-0.75 (-1.47 to 0.04)		.06
Deaths before ICU discharge, No. (%)	100 (14.66)	81 (11.89)	-2.77% (-8.08% to 2.52%)		.15
Hospital stay, mean (95% CI), d	24.7 (23.7 to 25.8)	25.4 (24.4 to 26.6)	0.7 (-1.4 to 3.1)		.50
Deaths before hospital discharge, No. (%)	151 (22.1)	140 (20.6)	-1.58% (-6.91% to 3.69%)		.51

ORIGINAL ARTICLE

Early versus On-Demand Nasoenteric Tube Feeding in Acute Pancreatitis

Table 2. Primary and Secondary End Points, According to the Intention-to-Treat Analysis.*

Outcome	Early Tube Feeding (N = 101)	On-Demand Tube Feeding (N = 104)	Risk Ratio (95% CI)	P Value
Primary composite end point: infection or death — no. (%)	30 (30)	28 (27)	1.07 (0.79–1.44)	0.76
Secondary end points				
Infection — no. (%)†	25 (25)	27 (26)	0.97 (0.70–1.34)	0.87
Infected pancreatic necrosis	9 (9)	15 (14)	0.74 (0.43–1.26)	0.28
Bacteremia	17 (17)	18 (17)	0.98 (0.68–1.43)	1.00
Pneumonia	12 (12)	13 (12)	0.97 (0.63–1.50)	1.00
Death — no. (%)	11 (11)	7 (7)	1.27 (0.85–1.89)	0.33
Necrotizing pancreatitis — no. (%)‡	64 (63)	65 (62)	1.06 (0.77–1.47)	0.76
CT severity index§	4±2	4±3	—	0.29
ICU admission after randomization — no. (%)	18 (18)	20 (19)	0.95 (0.66–1.38)	0.86
Mechanical ventilation — no. (%)	12 (12)	14 (13)	0.93 (0.60–1.44)	0.84
New-onset organ failure — no./total no. at risk (%)¶				
Single organ failure	26/67 (39)	31/73 (42)	0.92 (0.65–1.32)	0.73
Persistent single organ failure	10/67 (15)	10/73 (14)	1.05 (0.65–1.70)	1.00
Multiple organ failure	7/67 (10)	6/73 (8)	1.14 (0.67–1.95)	0.77
Persistent multiple organ failure	4/67 (6)	4/73 (5)	1.05 (0.51–2.14)	1.00

Trial of the Route of Early Nutritional Support in Critically Ill Adults


Table 3. Primary and Secondary Outcomes.*

Outcome	Parenteral Group (N= 1191)	Enteral Group (N= 1197)	Absolute Difference between Groups (95% CI)	Relative Risk (95% CI)	P Value
Primary outcome: death within 30 days — no./total no. (%)	393/1188 (33.1)	409/1195 (34.2)	1.15 (−2.65 to 4.94)†	0.97 (0.86 to 1.08)‡	0.57§
Secondary outcomes					
No. of days alive and free of specified organ support up to 30 days¶					
Free of advanced respiratory support	14.3±12.1	14.3±12.2	0.04 (−0.94 to 1.01)		0.94
Free of advanced cardiovascular support	18.9±13.5	18.5±13.6	0.41 (−0.63 to 1.53)		0.44
Free of renal support	19.1±13.9	18.8±14.0	0.26 (−0.85 to 1.47)		0.66
Free of neurologic support	19.2±13.8	18.9±14.0	0.34 (−0.81 to 1.36)		0.57
Free of gastrointestinal support	13.0±11.7	13.2±11.8	−0.12 (−1.05 to 0.80)		0.81
No. of treated infectious complica- tions per patient‡	0.22±0.60	0.21±0.56	0.01 (−0.04 to 0.06)		0.72
Noninfectious complications — no./total no. (%)					
Episodes of hypoglycemia	44/1191 (3.7)**	74/1197 (6.2)††	2.49 (0.75 to 4.22)†		0.006§
Elevated liver enzymes	212/1191 (17.8)	179/1197 (15.0)	−2.85 (−5.81 to 0.12)†		0.07§
Nausea requiring treatment	44/1191 (3.7)	53/1197 (4.4)	0.73 (−0.85 to 2.32)†		0.41§
Abdominal distention	78/1191 (6.5)	99/1197 (8.3)	1.72 (−0.38 to 3.82)†		0.12§
Vomiting	100/1191 (8.4)	194/1197 (16.2)	7.81 (5.20 to 10.43)†		<0.001§
New or substantially worsened pressure ulcers	181/1190 (15.2)	179/1195 (15.0)	−0.23 (−3.10 to 2.64)†		0.91§
Median no. of days in the ICU (IQR)‡‡	8.1 (4.0–15.8)	7.3 (3.9–14.3)			0.15
Median no. of days in acute care hospital (IQR)§§	17 (8–34)	16 (8–33)			0.32
Death — no./total no. (%)¶¶					
In the ICU	317/1190 (26.6)	352/1197 (29.4)		0.91 (0.80 to 1.03)	0.13§
In acute care hospital	431/1185 (36.4)	450/1186 (37.9)		0.96 (0.86 to 1.06)	0.44§
By 90 days	442/1184 (37.3)	464/1188 (39.1)		0.96 (0.86 to 1.06)	0.40§

Early versus Late Parenteral Nutrition in Critically Ill Adults

Michael P. Casaer, M.D., Dieter Mesotten, M.D., Ph.D.,
Greet Hermans, M.D., Ph.D., Pieter J. Wouters, R.N., M.Sc.,
Miet Schetz, M.D., Ph.D., Geert Meyfroidt, M.D., Ph.D.,
Sophie Van Cromphaut, M.D., Ph.D., Catherine Ingels, M.D.,
Philippe Meersseman, M.D., Jan Muller, M.D., Dirk Vlasselaers, M.D., Ph.D.,
Yves Debaveye, M.D., Ph.D., Lars Desmet, M.D., Jasperina Dubois, M.D.,
Aime Van Assche, M.D., Simon Vanderheyden, B.Sc.,
Alexander Wilmer, M.D., Ph.D., and Greet Van den Berghe, M.D., Ph.D.

B Discharge Alive from ICU




No. at Risk

Late initiation	2328	623	376	236
Early initiation	2312	694	418	253

Permissive Underfeeding or Standard Enteral Feeding in Critically Ill Adults


Yaseen M. Arabi, M.D., Abdulaziz S. Aldawood, M.D., Samir H. Haddad, M.D., Hasan M. Al-Dorzi, M.D., Hani M. Tamim, M.P.H., Ph.D., Gwynne Jones, M.D., Sangeeta Mehta, M.D., Lauralyn McIntyre, M.D., Othman Solaiman, M.D., Maram H. Sakkijha, R.D., Musharaf Sadat, M.B., B.S., and Lara Afesh, M.S.N., for the PermiT Trial Group*



No. at Risk

Standard feeding	446	380	352	334	325	322	319	315	312	308
Permissive underfeeding	448	390	368	346	340	331	330	326	326	324

—○— Permissive underfeeding —●— Standard feeding



CRITICAL CARE MEDICINE

Nutrition in the Acute Phase of Critical Illness

Michael P. Casaer, M.D., Ph.D., and Greet Van den Berghe, M.D., Ph.D.

Recommendations for clinical practice

Allow hypocaloric enteral feeding in the acute phase of critical illness for up to 7 days in previously well-nourished patients.

Note that current evidence does not support glutamine supplementation early in critical illness.

Supply micronutrients to prevent refeeding syndrome.*

Réhabilitation Précoce en Réanimation



ERAS

Information
Conselling



No bowel
preparation



Carbohydrate loading
No medication for sedation



Thrombo and
antimicrobial
prophylaxis



Anaesthetic protocol
Epidural analgesia



Preventing PONV



laparoscopy or
minimal length
incisions



No routine
nasogastric tube



Preventing intraop
hypothermia



Periop fluid
restriction



No routine
abdominal
drainage

Urinary drainage

Preventing
postoperative ileus



Postoperative epidural
analgesia



Early postoperative oral
diet



Early mobilization



Audit





En dehors du SDRA à la phase initiale et du cérébrolésé avec HTIC,

Pas de sédation profonde !

Gérald Chanques, Montpellier, France

- AWAKE
- BREATHE
- CHOICE OF DRUGS
- DELIRIUM
- EARLY MOBILIZATION



"All the News
That's Fit to Print"

The New York Times

Washington Edition

Today, a mix of sun and clouds, highs in low 40s. Tonight, partly cloudy, lows around 30. Tomorrow, thickening clouds, colder late, highs in low 40s. Weather map, Page 2.

L. CLVIII . . . No. 54,553

© 2009 The New York Times

MONDAY, JANUARY 12, 2009

\$1.

New Idea to Cut I.C.U. Trauma: Get Patients Up, Tubes and All

By GINA KOLATA

For years, doctors thought they had done their jobs if patients came out of an intensive care unit alive.

Now, though, researchers say they are alarmed by what they are finding as they track patients for months or years after an I.C.U. stay. Patients, even young ones, can be weak for years. Some have difficulty thinking and concentrating or have post-traumatic stress disorder and terrible memories of nightmares they had while heavily sedated.

While patients may be suffering lingering effects from illnesses that brought them to the I.C.U.,

researchers are increasingly convinced that spending days, weeks or months on life support in the units can elicit unexpected, long-lasting effects.

So now some I.C.U.'s are trying what seems like a radical solution: reducing sedation levels and getting patients up and walking even though they are gravely ill, complete with feeding tubes, intravenous lines and tethers to ventilators.

Even a few days in an I.C.U. can be physically devastating immediately afterward, said Dr. Naeem Ali of Ohio State University.

Continued on Page A11

New Approach to Cut Trauma From I.C.U.: Get Patients Walking

By GINA KOLATA

For years, doctors thought they had done their jobs if patients came out of an intensive care unit alive.

Now, though, researchers say they are alarmed by what they are finding as they track patients for months or years after an I.C.U. stay. Patients, even young ones, can be weak for years. Some have difficulty thinking and concentrating or have post-traumatic stress disorder and terrible memories of nightmares they had while heavily sedated.

While patients may be suffering lingering effects from illnesses that brought them to the I.C.U.,

researchers are increasingly convinced that spending days, weeks or months on life support in the units can elicit unexpected, long-lasting effects.

So now some I.C.U.'s are trying what seems like a radical solution: reducing sedation levels and getting patients up and walking even though they are gravely ill, complete with feeding tubes, intravenous lines and tethers to ventilators.

Even a few days in an I.C.U. can be physically devastating immediately afterward, said Dr. Naeem Ali of Ohio State University.

Continued on Page A11



... the researchers said. "We thought that these kids would be able to get up and walk and be able to eat and be able to think and be able to feel and be able to live."

... the researchers said. "We thought that these kids would be able to get up and walk and be able to eat and be able to think and be able to feel and be able to live."

... the researchers said. "We thought that these kids would be able to get up and walk and be able to eat and be able to think and be able to feel and be able to live."

... the researchers said. "We thought that these kids would be able to get up and walk and be able to eat and be able to think and be able to feel and be able to live."

... the researchers said. "We thought that these kids would be able to get up and walk and be able to eat and be able to think and be able to feel and be able to live."

Study of the Times: Getting Patients Up, Tubes and All


Study of the Times: Getting Patients Up, Tubes and All



Envisager
dés l'admission

Early intensive care unit mobility therapy in the treatment of acute respiratory failure*

Peter E. Morris, MD; Amanda Goad, RN; Clifton Thompson, RN; Karen Taylor, MPT; Bethany Harry, MPT; Leah Passmore, MS; Amelia Ross, RN, MSN; Laura Anderson; Shirley Baker; Mary Sanchez; Laretta Penley; April Howard, RN; Luz Dixon, RN; Susan Leach, RN; Ronald Small, MBA; R. Duncan Hite, MD; Edward Haponik, MD



Early intensive care unit mobility therapy in the treatment of acute respiratory failure*

Peter E. Morris, MD; Amanda Goad, RN; Clifton Thompson, RN; Karen Taylor, MPT; Bethany Harry, MPT; Leah Passmore, MS; Amelia Ross, RN, MSN; Laura Anderson; Shirley Baker; Mary Sanchez; Laretta Penley; April Howard, RN; Luz Dixon, RN; Susan Leach, RN; Ronald Small, MBA; R. Duncan Hite, MD; Edward Haponik, MD

	Usual Care (n = 135)	Protocol (n = 145)	<i>p</i>
Days to first out of bed	13.7 (11.7–15.7)	8.5 (6.6–10.5)	<.001
Days to first out of bed (adjusted ^a)	11.3 (9.6–13.4)	5.0 (4.3–5.9)	<.001
Ventilator days	9.0 (7.5–10.4)	7.9 (6.4–9.3)	.298
Ventilator days (adjusted ^a)	10.2 (8.7–11.7)	8.8 (7.4–10.3)	.163
ICU LOS days	8.1 (7.0–9.3)	7.6 (6.3–8.8)	.084
ICU LOS days (adjusted ^a)	6.9 (5.9–8.0)	5.5 (4.7–6.3)	.025
Hospital LOS days	17.2 (14.2–20.2)	14.9 (12.6–17.1)	.048
Hospital LOS days (adjusted ^a)	14.5 (12.7–16.7)	11.2 (9.7–12.8)	.006


Encore plus actif ?

Encore plus tôt ?

Disponible 24h/24 ?

Algorithme mobilisation précoce pour les IDE

Evaluation première
par
Kinésithérapeute






























Chez tous les patients ?

Evaluation de la douleur chez un patient communiquant







Conclusion

Réhabilitation Précoce en Réanimation

Possible

Recommandé



Special Article

Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit

- Delirium assessment should be routinely performed in all ICU patients (1B).
- The CAM-ICU and ICDSC delirium monitoring tools are the most valid and reliable scales to assess delirium in ICU patients (A).
- Mobilize ICU patients early when feasible to reduce the incidence and duration of delirium, and to improve functional outcomes (1B).
- Promote sleep in ICU patients by controlling light and noise, clustering patient care activities, and decreasing stimuli at night (1C).
- Avoid using rivastigmine to reduce the duration of delirium in ICU patients (1B).
- Suggest avoiding the use of antipsychotics in patients who are at risk for torsades de pointes (2B).
- Suggest not using benzodiazepines in ICU patients with delirium unrelated to ETOH/benzodiazepine withdrawal (2B).

- Delirium assessment should be routinely performed in all ICU patients (1B).
- The CAM-ICU and ICDSC delirium monitoring tools are the most valid and reliable scales to assess delirium in ICU patients (A).
- Mobilize ICU patients early when feasible to reduce the incidence and duration of delirium, and to improve functional outcomes (1B).
- Promote sleep in ICU patients by controlling light and noise, clustering patient care activities, and decreasing stimuli at night (1C).
- Avoid using rivastigmine to reduce the duration of delirium in ICU patients (1B).
- Suggest avoiding the use of antipsychotics in patients who are at risk for torsades de pointes (2B).
- Suggest not using benzodiazepines in ICU patients with delirium unrelated to ETOH/benzodiazepine withdrawal (2B).



- Delirium assessment should be routinely performed in all ICU patients (1B).
- The CAM-ICU and ICDSC delirium monitoring tools are the most valid and reliable scales to assess delirium in ICU patients (A).
- Mobilize ICU patients early when feasible to reduce the incidence and duration of delirium, and to improve functional outcomes (1B).
- Promote sleep in ICU patients by controlling light and noise, clustering patient care activities, and decreasing stimuli at night (1C).
- Avoid using rivastigmine to reduce the duration of delirium in ICU patients (1B).
- Suggest avoiding the use of antipsychotics in patients who are at risk for torsades de pointes (2B).
- Suggest not using benzodiazepines in ICU patients with delirium unrelated to ETOH/benzodiazepine withdrawal (2B).

Sédation

Hypotension

Dénutrition

Confusion

Oedemes

Ventilation

Réhabilitation
précoce
en Réa



Surviving the ICU Does Not Mean That the War Is Over

young man was a veteran, a survivor of an imaginary war he had fought over weeks and months.

The symptoms he described were clearly those of posttraumatic stress disorder (PTSD), a common

Merci de votre attention ...